Full-Time
Posted on 2/1/2022
Computational drug discovery for cancer therapies
No salary listed
Cambridge, MA, USA
Reverie Labs uses computational drug discovery to speed up cancer therapy development by partnering with pharmaceutical and biotech firms to identify and optimize drug candidates. Their approach blends machine learning, cheminformatics, physics, biology, and chemistry to build models and workflows that search chemical space and guide chemistry decisions. They differentiate themselves through an interdisciplinary team delivering practical, collaborative drug discovery programs, as shown by partnerships such as Roche/Genentech. The goal is to accelerate bringing cancer therapies to clinical trials by providing computational tools and collaborative programs that streamline discovery and optimization.
Company Size
1-10
Company Stage
Series A
Total Funding
$25.1M
Headquarters
Cambridge, Massachusetts
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
People at Reverie Labs who can refer or advise you
Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com. Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.
Reverie Labs, a company leveraging AI for drug discovery, has raised $25 million in venture capital funding.Read More
By zeroing in on a notorious class of enzymes associated with cancer, Reverie Labs puts the power of cloud computing to its full potential Can two smart, motivated college grads start a pharmaceutical company in an apartment with a few laptops? Just ask Jonah Kallenbach and Ankit Gupta, co-founders of Reverie Labs. Based in Cambridge, Reverie Labs is applying […]